Dan C Malone

Summary

Affiliation: University of Arizona
Country: USA

Publications

  1. ncbi request reprint Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions
    Daniel C Malone
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, PO Box 210207, Tucson, AZ 85721 0207, USA
    J Am Pharm Assoc (2003) 44:142-51. 2004
  2. ncbi request reprint Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer
    Lisa M Hess
    Arizona Cancer Center, University of Arizona, P O Box 245024, 1515 North Campbell Avenue, 2964A1 Tucson, AZ 85724, USA
    Cancer Epidemiol Biomarkers Prev 14:2579-83. 2005
  3. ncbi request reprint Health care decision makers' use of comparative effectiveness research: report from a series of focus groups
    Lorenzo Villa
    College of Pharmacy, The University of Arizona, 1295 N Martin Ave, Tucson, Arizona 85721, USA
    J Manag Care Pharm 19:745-54. 2013
  4. pmc Evaluation of a drug-drug interaction: fax alert intervention program
    Edward P Armstrong
    University of Arizona College of Pharmacy, Tucson, AZ 85721, USA
    BMC Med Inform Decis Mak 13:32. 2013
  5. ncbi request reprint Effect of an educational outreach program on prescribing potential drug-drug interactions
    Daniel C Malone
    Pharmacy Practice Science, College of Pharmacy, University of Arizona, 1295 N Martin, PO Box 210202, Tucson, AZ 85721, USA
    J Manag Care Pharm 19:549-57. 2013
  6. doi request reprint Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation
    Amanda R Harrington
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721 0202, USA
    Stroke 44:1676-81. 2013
  7. ncbi request reprint Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs
    Gregory W Daniel
    University of Arizona, 1295 N Martin, PO Box 210202, Tucson, AZ 85721 0202, USA
    J Manag Care Pharm 13:142-54. 2007
  8. doi request reprint A claims-based Markov model for Crohn's disease
    D C Malone
    University of Arizona College of Pharmacy, Tucson, 85721 0202, USA
    Aliment Pharmacol Ther 32:448-58. 2010
  9. ncbi request reprint Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program
    Daniel C Malone
    University of Arizona College of Pharmacy, PO Box 210207, Tucson, AZ 85721, USA
    J Manag Care Pharm 11:458-68. 2005
  10. ncbi request reprint A budget-impact and cost-effectiveness model for second-line treatment of major depression
    Daniel C Malone
    Center for Health Outcomes and PharmacoEconomic Research, University of Arizona College of Pharmacy, Tucson, AZ 85721, USA
    J Manag Care Pharm 13:S8-18. 2007

Detail Information

Publications59

  1. ncbi request reprint Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions
    Daniel C Malone
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, PO Box 210207, Tucson, AZ 85721 0207, USA
    J Am Pharm Assoc (2003) 44:142-51. 2004
    ..To develop a list of clinically important drug-drug interactions (DDIs) likely to be encountered in community and ambulatory pharmacy settings and detected by a computerized pharmacy system...
  2. ncbi request reprint Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer
    Lisa M Hess
    Arizona Cancer Center, University of Arizona, P O Box 245024, 1515 North Campbell Avenue, 2964A1 Tucson, AZ 85724, USA
    Cancer Epidemiol Biomarkers Prev 14:2579-83. 2005
    ..This study evaluates the association between participant self-reported study diary records and the weight of the medication vessel at each study visit, in the setting of a phase IIb topical chemoprevention trial...
  3. ncbi request reprint Health care decision makers' use of comparative effectiveness research: report from a series of focus groups
    Lorenzo Villa
    College of Pharmacy, The University of Arizona, 1295 N Martin Ave, Tucson, Arizona 85721, USA
    J Manag Care Pharm 19:745-54. 2013
    ..Comparative effectiveness research (CER) is a helpful approach to improve health outcomes by developing and disseminating evidence-based information to patients, clinicians, and other decision makers about the most effective interventions...
  4. pmc Evaluation of a drug-drug interaction: fax alert intervention program
    Edward P Armstrong
    University of Arizona College of Pharmacy, Tucson, AZ 85721, USA
    BMC Med Inform Decis Mak 13:32. 2013
    ..The purpose of this study was to determine if near-real time fax alerts for potential drug-drug interactions (PDDIs) would influence prescribing...
  5. ncbi request reprint Effect of an educational outreach program on prescribing potential drug-drug interactions
    Daniel C Malone
    Pharmacy Practice Science, College of Pharmacy, University of Arizona, 1295 N Martin, PO Box 210202, Tucson, AZ 85721, USA
    J Manag Care Pharm 19:549-57. 2013
    ..Ideally, such visits promote evidence-based knowledge, create trusting relationships, and induce practice change, particularly with regard to prescribing potentially interacting medications...
  6. doi request reprint Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation
    Amanda R Harrington
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ 85721 0202, USA
    Stroke 44:1676-81. 2013
    ..To estimate the cost-effectiveness of stroke prevention in patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg, dabigatran 150 mg, and rivaroxaban 20 mg compared with warfarin...
  7. ncbi request reprint Characteristics of older adults who meet the annual prescription drug expenditure threshold for medicare medication therapy management programs
    Gregory W Daniel
    University of Arizona, 1295 N Martin, PO Box 210202, Tucson, AZ 85721 0202, USA
    J Manag Care Pharm 13:142-54. 2007
    ....
  8. doi request reprint A claims-based Markov model for Crohn's disease
    D C Malone
    University of Arizona College of Pharmacy, Tucson, 85721 0202, USA
    Aliment Pharmacol Ther 32:448-58. 2010
    ..Crohn's disease is a chronic condition that often presents in early adulthood...
  9. ncbi request reprint Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program
    Daniel C Malone
    University of Arizona College of Pharmacy, PO Box 210207, Tucson, AZ 85721, USA
    J Manag Care Pharm 11:458-68. 2005
    ..The core WMP was a physician-supervised, multidisciplinary program for which each enrollee paid $100 out of pocket...
  10. ncbi request reprint A budget-impact and cost-effectiveness model for second-line treatment of major depression
    Daniel C Malone
    Center for Health Outcomes and PharmacoEconomic Research, University of Arizona College of Pharmacy, Tucson, AZ 85721, USA
    J Manag Care Pharm 13:S8-18. 2007
    ..Depressed patients who initially fail to achieve remission when placed on a selective serotonin reuptake inhibitor (SSRI) may require a second treatment...
  11. ncbi request reprint Burden of Alzheimer's disease and association with negative health outcomes
    Daniel C Malone
    College of Pharmacy, University of Arizona, Tucson, AZ 85721 0202, USA
    Am J Manag Care 15:481-8. 2009
    ..To examine the association of Alzheimer's disease (AD) with common chronic conditions, acute care events, and risk of hospitalization...
  12. doi request reprint Association of cardiometabolic risk factors and prevalent cardiovascular events
    Dan C Malone
    College of Pharmacy, University of Arizona, Tucson, Arizona 85721 0202, USA
    Metab Syndr Relat Disord 7:585-93. 2009
    ..This study evaluated cardiometabolic risk factors and their relationship to prevalent diagnosis of acute myocardial infarction (AMI) and stroke...
  13. ncbi request reprint Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy
    D C Malone
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona Health Sciences Center, 1703 E Mabel Street, Tucson, AZ 85721 0207, USA
    Respir Med 97:1269-76. 2003
    ..The median incremental cost-effectiveness ratio was dollars -5.77 (95% CI: dollars -68.08 to dollars -4.08). The results of this analysis indicate that HFA-BDP was a dominant therapy (more effective, less costly) compared to CFC-BDP...
  14. ncbi request reprint Evaluation of a wireless handheld medication management device in the prevention of drug-drug interactions in a Medicaid population
    Daniel C Malone
    College of Pharmacy, University of Arizona, 1295 N Martin, Tucson, AZ 85721 0202, USA
    J Manag Care Pharm 18:33-45. 2012
    ....
  15. ncbi request reprint Pharmacist workload and pharmacy characteristics associated with the dispensing of potentially clinically important drug-drug interactions
    Daniel C Malone
    College of Pharmacy, University of Arizona, Tucson 85721, USA
    Med Care 45:456-62. 2007
    ..The purpose of this study was to examine pharmacy characteristics that may be associated with dispensed potential DDIs...
  16. ncbi request reprint An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers
    D C Malone
    University of Colorado Health Sciences Center, School of Pharmacy, Denver, USA
    Pharmacotherapy 20:1149-58. 2000
    ..To determine if clinical pharmacists could affect economic resource use and humanistic outcomes in an ambulatory, high-risk population...
  17. ncbi request reprint Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C
    Daniel C Malone
    University of Arizona College of Pharmacy, PO Box 210207, Tucson, AZ 85721, USA
    J Manag Care Pharm 11:687-94. 2005
    ....
  18. ncbi request reprint Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia
    D C Malone
    College of Pharmacy, University of Arizona, Tucson 85721 0207, USA
    Ann Pharmacother 35:1180-5. 2001
    ..METHODs: A retrospective chart review of patients from community hospitals with a diagnosis of pneumonia at discharge admitted from December 1997 to May 1998. Data were collected based on American Thoracic Society (ATS) criteria...
  19. ncbi request reprint Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems?
    D C Malone
    University of Colordao Health Sciences Center, USA
    Med Care 39:113-22. 2001
    ..An objective of pharmaceutical care is for pharmacists to improve patients' health-related quality of life (HRQOL) by optimizing medication therapy...
  20. ncbi request reprint The role of pharmacoeconomic modeling in evidence-based and value-based formulary guidelines
    Daniel C Malone
    University of Arizona College of Pharmacy, Tucson, AZ 85721, USA
    J Manag Care Pharm 11:S7-10. 2005
    ..To review evidence-based medicine (EBM) in the context of pharmacoeconomic (PE) decision making by health care organizations...
  21. ncbi request reprint Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System
    Wei Shi Yeh
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona 85721, USA
    Pharmacotherapy 27:813-24. 2007
    ....
  22. doi request reprint Relationship between pharmaceutical services characteristics and exposure rates to drug-drug interactions in Veterans Affairs medical centers
    Maysaa H Mahmood
    PharmaceuticalSciences, College of Pharmacy, University of Arizona, Tucson 5721 0202, USA
    Am J Health Syst Pharm 65:1744-9. 2008
    ..The association between the exposure rates of clinically important drug-drug interactions (DDIs) and the structure of pharmaceutical services within the ambulatory care settings of Veterans Affairs medical centers (VAMCs) is discussed...
  23. ncbi request reprint Potential drug-drug interactions within Veterans Affairs medical centers
    Maysaa Mahmood
    Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona UA, Tucson, AZ 85721 0202, USA
    Am J Health Syst Pharm 64:1500-5. 2007
    ..This study assessed the prevalence of 25 clinically important drug-drug interactions (DDIs) in the ambulatory care clinics of the Department of Veterans Affairs medical centers (VAMCs)...
  24. ncbi request reprint Assessment of potential drug-drug interactions with a prescription claims database
    Daniel C Malone
    College of Pharmacy, University of Arizona, 1703 E Mabel, Tucson, AZ 85721, USA
    Am J Health Syst Pharm 62:1983-91. 2005
    ..The prevalence of 25 clinically important potential drug-drug interactions (DDIs) in a population represented by the drug claims database of a pharmacy benefit management company (PBM) was studied...
  25. ncbi request reprint Reasons provided by prescribers when overriding drug-drug interaction alerts
    Amy J Grizzle
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721 0202, USA
    Am J Manag Care 13:573-8. 2007
    ..To investigate prescribers' rationales for overriding drug-drug interaction (DDI) alerts and to determine whether these reasons were helpful to pharmacists as a part of prescription order verification...
  26. ncbi request reprint Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder
    Yu Ko
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Arizona, Tucson, Arizona 85721 0207, USA
    Pharmacotherapy 26:1694-702. 2006
    ..To compare the cost-effectiveness of various antimuscarinic agents for the treatment of overactive bladder (OAB)...
  27. ncbi request reprint A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder
    Edward P Armstrong
    College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
    Curr Med Res Opin 24:1115-21. 2008
    ..To estimate the costs and quality-adjusted life weeks of duloxetine and escitalopram...
  28. pmc Practitioners' views on computerized drug-drug interaction alerts in the VA system
    Yu Ko
    College of Pharmacy, University of Arizona, Drachman B307F, 1295 N Martin, Tucson, AZ 85721 0207, USA
    J Am Med Inform Assoc 14:56-64. 2007
    ..To assess Veterans Affairs (VA) prescribers' and pharmacists' opinions about computer-generated drug-drug interaction (DDI) alerts and obtain suggestions for improving DDI alerts...
  29. ncbi request reprint Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures
    Lisa M Hess
    Arizona Cancer Center, University of Arizona, Tucson, 85724, USA
    Ann Pharmacother 40:1280-88. 2006
    ..These measures have focused on improving the accuracy of adherence measures or clarifying the evaluation time frame. As a result, there are many measures used to assess adherence that may or may not be comparable or accurate...
  30. ncbi request reprint Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies
    Jacob Abarca
    Center for Health Outcomes and PharmacoEconomic Research, University of Arizona College of Pharmacy, P O Box 210202 Tucson, AZ 85721 0202, USA
    J Manag Care Pharm 12:383-9. 2006
    ..Computerized drug-drug interaction (DDI) screening is widely used to identify potentially harmful drug combinations in the inpatient and outpatient setting...
  31. ncbi request reprint Workload and availability of technology in metropolitan community pharmacies
    Grant H Skrepnek
    Center for Health Outcomes and PharmarcoEconomic Research, College of Pharmacy, University of Arizona, 1703 East Mabel Street, Tucson, AZ 85721, USA
    J Am Pharm Assoc (2003) 46:154-60. 2006
    ..To assess workload characteristics and the presence of prescription processing technologies within metropolitan community pharmacies in the United States...
  32. doi request reprint Development of computerized alerts with management strategies for 25 serious drug-drug interactions
    John E Murphy
    College of Pharmacy, The University of Arizona, Tucson, AZ 85721 0202, USA
    Am J Health Syst Pharm 66:38-44. 2009
    ..The development of computerized alerts with management strategies for 25 drug-drug interactions (DDIs) is described...
  33. ncbi request reprint Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities
    Marie E Gardner
    College of Pharmacy, The University of Arizona, Tucson, AZ, USA
    J Am Med Dir Assoc 5:101-6. 2004
    ..Depression is a common, treatable disorder among nursing facility residents...
  34. ncbi request reprint Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalization
    Jacob Abarca
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona, USA
    Pharmacotherapy 24:351-7. 2004
    ..To evaluate the effect of angiotensin-converting enzyme (ACE) inhibitor therapy on risk of hospitalization and resource utilization in patients with heart failure enrolled in a managed care organization...
  35. ncbi request reprint Cost-effectiveness analysis of simvastatin and lovastatin/extended- release niacin to achieve LDL and HDL goal using NHANES data
    Edward P Armstrong
    Department of Pharmacy Practice, Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA
    J Manag Care Pharm 10:251-8. 2004
    ..The purpose of this study was to compare 2 regimens achieving simultaneous LDL and HDL goals...
  36. ncbi request reprint An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care
    Grant H Skrepnek
    Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, College of Pharmacy, Tucson, AZ 85721, USA
    Curr Med Res Opin 21:261-70. 2005
    ..Study design: Retrospective managed care database analysis...
  37. ncbi request reprint Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit
    Jacob Abarca
    University of Arizona College of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, 1703 E Mabel, P O Box 210207, Tucson, AZ 85721 0207, USA
    J Manag Care Pharm 10:538-42. 2004
    ..To describe the dosing of etanercept and infliximab for the treatment of rheumatoid arthritis (RA)...
  38. ncbi request reprint Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs
    Grant H Skrepnek
    College of Pharmacy, University of Arizona, Tucson, AZ 85721 0207, USA
    Ann Pharmacother 39:1785-91. 2005
    ..Inappropriate medication use in patients with heart failure (HF) presents challenges in providing optimal, evidence-based care...
  39. ncbi request reprint Community pharmacy managers' perception of computerized drug-drug interaction alerts
    Jacob Abarca
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, P O Box 210207, Tucson, AZ 85721 0207, USA
    J Am Pharm Assoc (2003) 46:148-53. 2006
    ..To examine community pharmacists' attitudes toward computerized drug-drug interaction (DDI) alerts and identify factors associated with more favorable perceptions of these alerts...
  40. ncbi request reprint The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents
    Edward P Armstrong
    College of Pharmacy, University of Arizona, Tuczon, AZ 85721, USA
    Clin Ther 25:1-18. 2003
    ..Both nonselective and selective nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to increase blood pressure (BP)...
  41. pmc Physicians' opinions of a health information exchange
    Ana Lucia Hincapie
    Department of Pharmacy Practice and Science, The Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, Arizona, USA
    J Am Med Inform Assoc 18:60-5. 2011
    ..Arizona Medicaid developed a Health Information Exchange (HIE) system called the Arizona Medical Information Exchange (AMIE)...
  42. ncbi request reprint Concordance of severity ratings provided in four drug interaction compendia
    Jacob Abarca
    Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson 85721 0207, USA
    J Am Pharm Assoc (2003) 44:136-41. 2004
    ..To evaluate the agreement among drug-drug interaction (DDI) compendia as to designation of interactions as having the greatest clinical importance ("major" DDIs)...
  43. doi request reprint Gender and age differences in medications dispensed from a national chain drugstore
    Marietta Anthony
    The Critical Path Institute, Tucson, Arizona 85718, USA
    J Womens Health (Larchmt) 17:735-43. 2008
    ..Our objective was to compare sex and age differences in the medications dispensed in pharmacies from a large national drugstore chain...
  44. doi request reprint Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy
    Scott L Charland
    School of Pharmacy, University of Colorado, 258 Leland Creek Circle, Box 1941, Winter Park, CO 80482 1941, USA
    Curr Med Res Opin 26:365-75. 2010
    ..With numerous treatment options for managing dyslipidemia, it is important to evaluate agents that result in the greatest reduction of CVEs...
  45. ncbi request reprint Development and validation of a diabetes mellitus severity index: a risk-adjustment tool for predicting health care resource use and costs
    Vijay N Joish
    Department of Pharmacotherapy, College of Pharmacy, Pharmacotherapy Outcomes Research Center, University of Utah, Salt Lake City, 84108, USA
    Pharmacotherapy 25:676-84. 2005
    ..To develop and validate a diabetes mellitus-specific risk-adjustment tool--the diabetes severity index (DSI)--to assist in predicting health care costs and resources within populations of patients with diabetes...
  46. ncbi request reprint Profiling quality of diabetes care in a Veterans Affairs Healthcare System
    Vijay N Joish
    The University of Arizona, Tucson, USA
    Am J Med Qual 19:112-20. 2004
    ....
  47. ncbi request reprint Accuracy of adverse-drug-event reports collected using an automated dispensing system
    Andrew V Romero
    University Medical Center, Tucson, AZ, USA
    Am J Health Syst Pharm 62:1375-80. 2005
    ..The accuracy of adverse-drug-event (ADE) reports collected using an automated dispensing system was evaluated...
  48. ncbi request reprint Performance of drug-drug interaction software for personal digital assistants
    Natalie A Perkins
    El Rio Health Center Special Immunology Associates, Tucson, AZ, USA
    Ann Pharmacother 40:850-5. 2006
    ..However, PDAs can only be as effective as the software programs they use...
  49. ncbi request reprint A cost-benefit analysis of vision screening methods for preschoolers and school-age children
    Vijay N Joish
    Department of Pharmacy Practice and Sciences, College of Pharmacy, The University of Anzona, Tucson 85721 0284, USA
    J AAPOS 7:283-90. 2003
    ..The purpose of this study was to determine costs and benefits of visual acuity screening (VAS) or photoscreening (PS) in children...
  50. ncbi request reprint Health services use and health care costs of obese and nonobese individuals
    Marsha A Raebel
    Clinical Research Unit, Kaiser Permanente of Colorado, Denver, CO 80237, USA
    Arch Intern Med 164:2135-40. 2004
    ..Obesity has clinical and economic consequences. Few studies have compared health care resource utilization between age- and sex-matched obese and nonobese persons...
  51. ncbi request reprint Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real-world analysis
    Edward P Armstrong
    College of Pharmacy, University of Arizona, Tucson 85721, USA
    Pharmacotherapy 22:1117-23. 2002
    ..To compare the impact of fluticasone propionate versus three leukotriene modifiers-montelukast, zafirlukast, and zileuton-on the cost of asthma within a managed care organization...
  52. pmc Pharmacy students' ability to identify potential drug-drug interactions
    Kim R Saverno
    University of Arizona College of Pharmacy, USA
    Am J Pharm Educ 73:27. 2009
    ..To evaluate the ability of third- and fourth-year pharmacy students to identify clinically significant drug-drug interactions (DDIs)..
  53. ncbi request reprint Comparison of peptic-ulcer drug use and expenditures before and after the implementation of a government policy to separate prescribing and dispensing practices in South Korea
    Eui Kyung Lee
    Division of Health Research, Korea Institute for Health and Social Affairs, Seoul, South Korea
    Clin Ther 25:578-92. 2003
    ..It was hoped that this policy would promote the rational use of medications and reduce medication expenditures, which accounted for approximately 30% of the total health care expenditures before the implementation of SPD...
  54. doi request reprint Use of salmeterol with and without concurrent use of inhaled corticosteroids and the risk of asthma-related hospitalization among patients with asthma
    Meng Ting Wang
    School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, Republic of China
    Curr Med Res Opin 24:859-67. 2008
    ..Studies evaluating the safety of salmeterol are inconclusive, which might be the result from not taking into account the impact of concomitant inhaled corticosteroids (ICS)...
  55. ncbi request reprint Consumer understanding and satisfaction associated with a 3-tier prescription drug benefit
    Bridget M Olson
    Eli Lilly and Company, 9872 Saskatchewan Ave, San Diego, CA 92129, USA
    J Manag Care Pharm 11:480-92. 2005
    ..The purpose of this research was to investigate consumer understanding and satisfaction associated with a 3-tier prescription drug benefit among users of the prescription drug benefit...
  56. ncbi request reprint Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers
    Yu Ko
    Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore
    Drug Saf 31:525-36. 2008
    ....
  57. ncbi request reprint Studying pharmaceutical care: difficult but necessary
    Dale B Christensen
    University of North Carolina School of Pharmacy, Chapel Hill, USA
    J Am Pharm Assoc (2003) 43:S36-7. 2003
    ..Demonstrating changes in patient satisfaction with providers and in health-related quality of life is difficult...
  58. ncbi request reprint Gastrointestinal disease control after histamine2-receptor antagonist dose modification for renal impairment in frail chronically ill elderly patients
    Thomas E Lackner
    University of Minnesota, College of Pharmacy and Institute for the Study of Geriatric Pharmacotherapy, Minneapolis, USA
    J Am Geriatr Soc 51:650-6. 2003
    ..To determine whether histamine2-receptor antagonist (H2RA) dose modified for renal impairment affects gastrointestinal (GI) disease control...
  59. ncbi request reprint Using indirect comparisons in pharmacoeconomic studies--time for implementation
    Daniel C Malone
    Clin Ther 29:2454-5. 2007